Arcus Biosciences (RCUS) Other Non-Current Assets (2017 - 2026)

Arcus Biosciences' Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $61.0 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets fell 14.08% year-over-year to $61.0 million in Q1 2026; TTM through Mar 2026 was $61.0 million, a 14.08% decrease from a year earlier, with the FY2025 full-year figure at $63.0 million, down 13.7% from the prior year.
• Other Non-Current Assets eased to $61.0 million in Q1 2026 per RCUS's latest filing, from $63.0 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $114.0 million in Q4 2022 and bottomed at $3.0 million in Q2 2022.
• The 5-year median for Other Non-Current Assets is $71.0 million (2025), against an average of $64.5 million.
• Biggest YoY gain for Other Non-Current Assets was 3527.29% in 2023; the steepest drop was 94.74% in 2023.
• Year by year, Other Non-Current Assets stood at $114.0 million in 2022, then slumped by 94.74% to $6.0 million in 2023, then surged by 1116.67% to $73.0 million in 2024, then decreased by 13.7% to $63.0 million in 2025, then dropped by 3.17% to $61.0 million in 2026.
• Per Business Quant, the three latest RCUS Other Non-Current Assets figures stand at $61.0 million (Q1 2026), $63.0 million (Q4 2025), and $65.0 million (Q3 2025).